
Appendix 1: Flowchart to classify presumed cause of infection



CRP, c-reactive protein; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection. *Patients could have identified viral co-infection. (1)

References

1. Hagedoorn NN, Borensztajn DM, Nijman R, et al. Variation in antibiotic prescription rates in febrile children presenting to emergency departments across Europe (MOFICHE): A multicentre observational study. *PLOS Medicine*. 2020;17:e1003208.

Appendix 2. Additional methods: multiple imputation

Missing data

For the main analysis, we excluded patients without systolic blood pressure (BP) measurement. We used multiple imputation by chained equations using the MICE package in R to impute referral, comorbidity, temperature, heart rate, capillary refill time and consciousness. We included hospital, all outcome measures and other auxiliary variables influencing case-mix and disease severity in the imputation model. Multiple imputation was performed on all patients (n=32,766). For the statistical analysis where we used the multiple imputation data, results were pooled for a final result. For the main analysis, patients with missing systolic BP measurement were excluded leading to 5648 eligible visits.

For the sensitivity analysis, we used a different approach to deal with missing BP data. We selected the five EDs with >20% BP measurements (n=12,385), and imputed missing BP values in this subset. In this subset we repeated all analysis from part 2. Proportion of missingness of variables are provided in Table 1 and Appendix 5.

General characteristics	Markers of disease severity	Vital signs	Diagnostics	Treatment	Outcomes
Hospital	Triage urgency	Heart rate	CRP-level	Immediate life-saving interventions	Disposition
Age	Fever duration	Respiratory rate	Chest X-ray categories	Oxygen treatment	Final diagnosis
Sex	Ill appearance	Temperature	Urinalysis categories	Inhalation medication	Focus of infection
Referral type (self / GP / emergency services / other)	Work of breathing	Capillary refill time	Blood culture performed	Antibiotic prescription type	Serious bacterial infection
Previous medical care (yes, primary care / yes, this ED / yes other secondary care)	Consciousness	Oxygen saturation	Cerebrospinal fluid performed	Antibiotic prescription mode	Invasive bacterial infection
Season	Meningeal signs	Non-invasive systolic blood pressure			
Comorbidity	Focal neurology				
Complex comorbidity	Non-blanching rash				
	Dehydration Seizures				

Variables in the multiple imputation model:

Appendix 3. Further details of serious bacterial infections (n=461), invasive bacterial infections (n=46) and immediate-lifesaving interventions (n=203)

Infection focus of serious bacterial infections (n=461)	N (%)
Urinary tract	153 (33.2%)
Lower respiratory tract infection	139 (30.2%)
Gastro intestinal or surgical abdomen	93 (20.2%)
Sepsis	37 (8.0%)
Musculoskeletal	15 (3.3%)
Meningitis / CNS infection	10 (2.2%)
Other	14 (3.0%)

Invasive bacterial infections (n=46)	N (%)
Bacteraemia*	40 (87%)
Bacterial meningitis*	6 (13%)
Bone and joint	2 (4.3%)

*Two patients had both bacteraemia and bacterial meningitis

Immediate life-saving interventions (n=203)*	N (%)	
Airway/breathing interventions	100 (49.3%)	
Haemodynamic interventions	112 (55.2%)	
Emergency medications	52 (26.6%)	

*Multiple categories per patients possible

Appendix 4. Patient characteristics of patients with blood pressure measurement and patients without blood pressure measurement

n (%)Missingn (%)General characteristics2.6 (1.3-5.2)Age in years, median (IQR)4.2 (1.8-8.5)2.6 (1.3-5.2)Female2548 (45.3)12172 (45.3)Comorbidity1338 (23.8)913831 (14.3)Comorbidity530 (9.4)91931 (3.5)Referred2354 (41.9)11011028 (41.1)Triage urgency26418670 (69.6)High: immediate, very urgent, intermediate1746 (31.1)7292 (27.2)Clinical symptoms7041.5 (0.5-3)704Fever duration in days, median (IQR)1.5 (0.5-3)7041.5 (0.5-3)III appearance868 (15.4)6214855 (18.1)Decreased consciousness82 (1.5)9087 (0.3)Vital signs716 (36.8-38.4)48037.7 (37.0-38.4)Hypoxia <95%2920(5.2)211935 (3.5)Prolonged capillary refill (>3 sec)105 (1.9)866254 (0.9)Tachycardia (APLS)1667 (29.7)555537 (20.6)Diagnostics and treatment120 (5-61)337817 (5-47)Blood cultures performed967 (17.2)1798 (6.7)Cerebrospinal fluid performed140 (2.5)198 (0.7)Antibiotic treatment following ED visit1983 (35.2)558305 (30.9)Admission to the ward >24 hours1159 (20.6)1375415 (20.2)	No blood pressure measured (n=26841)	
Age in years, median (IQR) $4.2 (1.8-8.5)$ $2.6 (1.3-5.2)$ Female $2548 (45.3)$ $12172 (45.3)$ Comorbidity $1338 (23.8)$ 91 $3831 (14.3)$ Complex comorbidity $530 (9.4)$ 91 $931 (3.5)$ Referred $2354 (41.9)$ 110 $11028 (41.1)$ Triage urgency 264 $11028 (41.1)$ Low: standard, non-urgent $3612 (64.2)$ $18670 (69.6)$ High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptoms 704 $1.5 (0.5-3)$ Fever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ III appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signs T $7920 (5.2)$ 211 Temperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia < 95% $2920(5.2)$ 211 $935 (3.5)$ Prolonged capillary refill (>3 sec) $105 (1.9)$ 866 $254 (0.9)$ Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatment $140 (2.5)$ $198 (0.7)$ Reformed $967 (17.2)$ $1798 (6.7)$ Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED visit $1983 (35.2)$ 55 $8305 (30.9)$ Admission to the ward >24 hours $1159 (20.6)$ 137 $5415 (20.2)$	Missing	
Female $2548 (45.3)$ $12172 (45.3)$ Comorbidity $1338 (23.8)$ 91 $3831 (14.3)$ Complex comorbidity $530 (9.4)$ 91 $931 (3.5)$ Referred $2354 (41.9)$ 110 $11028 (41.1)$ Triage urgency 264 $11028 (41.1)$ Low: standard, non-urgent $3612 (64.2)$ $18670 (69.6)$ High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptoms $7292 (27.2)$ $7292 (27.2)$ Clinical symptoms $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Fever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signs $77 (37.0-38.4)$ $935 (3.5)$ Prolonged capillary refill (>3 sec) $105 (1.9)$ 866 $254 (0.9)$ Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatment $77 (5-47)$ $1798 (6.7)$ Cloc cultures performed $967 (17.2)$ $1798 (6.7)$ Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED visit $1983 (35.2)$ 55 $8305 (30.9)$ Admission to the ward >24 hours $1159 (20.6)$ 137 $5415 (20.2)$		
Comorbidity1338 (23.8)913831 (14.3)Complex comorbidity530 (9.4)91931 (3.5)Referred2354 (41.9)11011028 (41.1)Triage urgency26418670 (69.6)High: immediate, very urgent, intermediate1746 (31.1)7292 (27.2)Clinical symptoms7041.5 (0.5-3)704Fever duration in days, median (IQR)1.5 (0.5-3)7041.5 (0.5-3)Ill appearance868 (15.4)6214855 (18.1)Decreased consciousness82 (1.5)9087 (0.3)Vital signsTemperature in °C, median (IQR)37.6 (36.8-38.4)48037.7 (37.0-38.4)Hypoxia <95%		
Complex comorbidity $530 (9.4)$ 91 $931 (3.5)$ Referred $2354 (41.9)$ 110 $11028 (41.1)$ Triage urgency 264 $11028 (41.1)$ Low: standard, non-urgent $3612 (64.2)$ $18670 (69.6)$ High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptomsFever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Referred Consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%		
Referred $2354 (41.9)$ 110 $11028 (41.1)$ Triage urgency 264 264 $18670 (69.6)$ Low: standard, non-urgent $3612 (64.2)$ $18670 (69.6)$ High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptomsFever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 87 (0.3)Vital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%	182	
Triage urgency264Low: standard, non-urgent $3612 (64.2)$ $18670 (69.6)$ High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptomsFever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signs $7292 (27.2)$ $87 (0.3)$ Temperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%	182	
Low: standard, non-urgent High: immediate, very urgent, intermediate $3612 (64.2)$ $1746 (31.1)$ $18670 (69.6)$ $7292 (27.2)$ Clinical symptoms1746 (31.1) $7292 (27.2)$ Clinical symptomsFever duration in days, median $(1QR)$ $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95% $2920(5.2)$ 211 $935 (3.5)$ Prolonged capillary refill (>3 sec) $105 (1.9)$ 866 $254 (0.9)$ Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatmentCRP in mg/L, median (IQR) $20 (5-61)$ 3378 $17 (5-47)$ Blood cultures performed $967 (17.2)$ $198 (0.7)$ Antibiotic treatment following ED visit $1983 (35.2)$ 55 $8305 (30.9)$ Admission to the ward >24 hours $1159 (20.6)$ 137 $5415 (20.2)$	1044	
High: immediate, very urgent, intermediate $1746 (31.1)$ $7292 (27.2)$ Clinical symptoms1.5 (0.5-3)7041.5 (0.5-3)Fever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance868 (15.4)6214855 (18.1)Decreased consciousness82 (1.5)9087 (0.3)Vital signsVital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Prolonged capillary refill (>3 sec)105 (1.9)866254 (0.9)Tachycardia (APLS)1667 (29.7)555537 (20.6)Diagnostics and treatment20 (5-61)337817 (5-47)Blood cultures performed967 (17.2)1798 (6.7)Creebrospinal fluid performed140 (2.5)198 (0.7)Antibiotic treatment following ED visit1983 (35.2)558305 (30.9)Admission to the ward >24 hours1159 (20.6)1375415 (20.2)	879	
Intermediate $1740 (51.1)$ $7292 (21.2)$ Clinical symptoms1.5 (0.5-3)7041.5 (0.5-3)Fever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signs $7292 (21.2)$ $87 (0.3)$ Temperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 Hypoxia <95%		
Fever duration in days, median (IQR) $1.5 (0.5-3)$ 704 $1.5 (0.5-3)$ Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%		
IQR)1.5 (0.5-3)7041.5 (0.5-3)Ill appearance $868 (15.4)$ 621 $4855 (18.1)$ Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signsFemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%		
Decreased consciousness $82 (1.5)$ 90 $87 (0.3)$ Vital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%	1676	
Vital signsVital signsTemperature in °C, median (IQR) $37.6 (36.8-38.4)$ 480 $37.7 (37.0-38.4)$ Hypoxia <95%	1040	
37.6 37.6 37.6 37.7 $37.$	210	
Hypoxia <95% $2920(5.2)$ 211 $935 (3.5)$ Prolonged capillary refill (>3 sec) $105 (1.9)$ 866 $254 (0.9)$ Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatmentCRP in mg/L, median (IQR) $20 (5-61)$ 3378 $17 (5-47)$ Blood cultures performed $967 (17.2)$ $1798 (6.7)$ Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED $1983 (35.2)$ 55 $8305 (30.9)$ Visit $1159 (20.6)$ 137 $5415 (20.2)$		
Prolonged capillary refill (>3 sec) $105 (1.9)$ 866 $254 (0.9)$ Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatment $20 (5-61)$ 3378 $17 (5-47)$ Blood cultures performed $967 (17.2)$ $1798 (6.7)$ Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED $1983 (35.2)$ 55 8305 (30.9) $8305 (30.9)$	2432	
Tachycardia (APLS) $1667 (29.7)$ 55 $5537 (20.6)$ Diagnostics and treatment $20 (5-61)$ 3378 $17 (5-47)$ CRP in mg/L, median (IQR) $20 (5-61)$ 3378 $17 (5-47)$ Blood cultures performed $967 (17.2)$ $1798 (6.7)$ Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED $1983 (35.2)$ 55 $8305 (30.9)$ visit $1159 (20.6)$ 137 $5415 (20.2)$	5204	
Diagnostics and treatment 20 (5-61) 3378 17 (5-47) CRP in mg/L, median (IQR) 20 (5-61) 3378 17 (5-47) Blood cultures performed 967 (17.2) 1798 (6.7) Cerebrospinal fluid performed 140 (2.5) 198 (0.7) Antibiotic treatment following ED visit 1983 (35.2) 55 8305 (30.9) Admission to the ward >24 hours 1159 (20.6) 137 5415 (20.2)	3004	
CRP in mg/L, median (IQR) $20 (5-61)$ 3378 $17 (5-47)$ Blood cultures performed967 (17.2)1798 (6.7)Cerebrospinal fluid performed140 (2.5)198 (0.7)Antibiotic treatment following ED1983 (35.2)558305 (30.9)Visit1159 (20.6)1375415 (20.2)	3372	
Blood cultures performed 967 (17.2) 1798 (6.7) Cerebrospinal fluid performed 140 (2.5) 198 (0.7) Antibiotic treatment following ED 1983 (35.2) 55 8305 (30.9) Admission to the ward >24 hours 1159 (20.6) 137 5415 (20.2)		
Cerebrospinal fluid performed $140 (2.5)$ $198 (0.7)$ Antibiotic treatment following ED $1983 (35.2)$ 55 $8305 (30.9)$ visit $1159 (20.6)$ 137 $5415 (20.2)$	13021	
Antibiotic treatment following ED 1983 (35.2) 55 8305 (30.9) visit 1159 (20.6) 137 5415 (20.2)		
Antibiotic treatment following ED 1983 (35.2) 55 8305 (30.9) visit 1159 (20.6) 137 5415 (20.2)		
	398	
	328	
Serious illness		
Serious bacterial infection 461 (8.2) 1683 (6.3)		
Invasive bacterial infection $46(0.8)$ $82(0.3)$		
Admission to the ICU69 (1.2)76 (0.3)Immediate life-saving interventions203 (3.6)212 (0.8)		

APLS, advanced paediatric life support; CRP, C-reactive protein; ICU, intensive care unit; IQR, interquartile range; NA, not applicable

Age group	Ν	Shock Index	Shock Index
88 I		Mean (SD)	95 th centile
<3m	181	1.83 (0.48)	2.62
3-6m	163	1.63 (0.34)	2.19
6m-1y	430	1.54 (0.29)	2.02
1-2y	753	1.45 (0.29)	1.96
2-3y	574	1.36 (0.25)	1.88
3-4y	549	1.28 (0.22)	1.77
4-5y	462	1.24 (0.23)	1.64
5-6y	406	1.18 (0.21)	1.62
6-7y	276	1.13 (0.21)	1.53
7-8y	234	1.09 (0.21)	1.47
8-9y	196	1.05 (0.22)	1.44
9-10y	185	1.01 (0.20)	1.41
10-11y	166	1.00 (0.20)	1.35
11-12y	157	0.98 (0.21)	1.34
12-13y	139	0.90 (0.19)	1.33
13-14y	127	0.93 (0.24)	1.21
14-15y	159	0.92 (0.21)	1.32
15-16y	122	0.92 (0.21)	1.26
16-17y	99	0.85 (0.21)	1.26
17-18y	131	0.87 (0.23)	1.21
SD, standard devi	iation; m	, months; y, year	

Appendix 5. Shock Index reference values according to age, n=5509

Appendix 6. Shock Index cut-off values for the different

outcomes, stratified for age groups

Serious bacterial infection	Shock Index cut- off value*	Sensitivity	Specificity	Negative LR	Positive LR
Age <1 year	1.37	0.91	0.24	0.37	1.20
Age 1-5 year	1.12	0.90	0.18	0.54	1.10
Age 5-10 year	0.81	0.91	0.08	1.21	0.98
Age >10 year	0.67	0.90	0.11	0.88	1.02
Invasive bacterial infection	Shock Index cut- off value*	Sensitivity	Specificity	Negative LR	Positive LR
Age <1 year	1.43	1.00	0.31	0.00	1.45
Age 1-5 year	1.19	0.92	0.29	0.29	1.28
Age 5-10 year	0.79	0.92	0.07	1.26	0.98
Age >10 year	0.93	0.91	0.54	0.17	1.98
Immediate life-saving intervention	Shock Index cut- off value*	Sensitivity	Specificity	Negative LR	Positive LR
Age <1 year	1.40	0.91	0.27	0.34	1.24
Age 1-5 year	1.06	0.91	0.12	0.78	1.03
Age 5-10 year	0.96	0.92	0.25	0.33	1.22
Age >10 year	0.79	0.92	0.29	0.29	1.29
ICU admission	Shock Index cut- off value*	Sensitivity	Specificity	Negative LR	Positive LR
Age <1 year	1.32	0.94	0.18	0.33	1.14
Age 1-5 year	1.11	0.94	0.13	0.56	1.09
11ge 1-5 year	0.69	0.00	0.17	4.25	1.02

0.93

1.00

* minimal sensitivity >=90% and maximal specificity

Age 5-10 year

Age >10 year

0.68

0.53

0.02

0.01

0.94

1.01

4.25

0.00

Appendix 7. Sensitivity analysis for febrile children in 5 EDs with >20% SBP measurement (n=12347)

Univariate and multivariate analysis of Shock Index >95 th centile values for serious illness (n=12347)					
	Shock Inde	x >95 th centile value			
	OR (95% CI)	Adj. OR (95% CI)*			
SBI	1.7 (1.2-2.4)	1.4 (1.0-2.0)			
n=643	1.7 (1.2-2.4)	1.4 (1.0-2.0)			
IBI	2.0 (0.8-4.8)	1.7 (0.7-4.1)			
n=81	2.0 (0.8-4.8)	1.7 (0.7-4.1)			
ILSI	2.6 (1.8-3.8)	2.4 (1.6-3.6)			
n=336	2.0 (1.0-5.0)				
ICU admission	2.9 (1.5-5.5)	3.0 (1.5-5.8)			
n=90	· · ·	5.0 (1.5-5.0)			

*Adjusted for age, sex, referral (y/n), comorbidity (y/n), temperature

Adj, adjusted; CI, confidence interval; ICU, intensive care unit; OR, odds ratio

Diagnostic performance of high Shock Index >95 th centile for serious illness (n=12347)						
	Sensitivity	Specificity	Positive LR	Negative LR		
	(95% CI)	(95% CI)	(95% CI)	(95% CI)		
SBI	0.08 (0.06-0.10)	0.97 (0.96-0.97)	2.4 (1.8-3.2)	0.95 (0.93-0.97)		
IBI	0.10 (0.04-0.19)	0.97 (0.96-0.97)	2.9 (1.5-5.7)	0.93 (0.87-1.00)		
ILSI	0.13 (0.09-0.17)	0.97 (0.96-0.97)	3.9 (2.9-5.3)	0.90 (0.87-0.94)		
ICU admission	0.14 (0.08-0.23)	0.97 (0.96-0.97)	4.3 (2.6-7.20)	0.89 (0.81-0.96)		

	SBI	IBI	ILSI	ICU admission
	AUC	AUC	AUC	AUC
	(95% CI)	(95% CI)	(95% CI)	(95% CI)
Shock Index				
(continuous)				
stratified for age				
<1 year, n=2337	0.63 (0.57-0.68)	0.71 (0.58-0.84)	0.69 (0.61-0.77)	0.71 (0.59-0.83)
1-5 year, n=6064	0.55 (0.51-0.60)	0.56 (0.42-0.69)	0.59 (0.54-0.65)	0.57 (0.46-0.67)
5-10 year, n=2484	0.53 (0.46-0.59)	0.65 (0.50-0.81)	0.56 (0.48-0.64)	0.53 (0.36-0.69)
>10 year, n= 1462	0.59 (0.53-0.65)	0.63 (0.46-0.80)	0.66 (0.59-0.74)	0.73 (0.48-0.98)

AUC, area under the curve; CI, confidence interval; IBI, invasive bacterial infection; ICU, intensive care unit; ILSI, immediate life-saving intervention; SBI, serious bacterial infection

Appendix 8: Members of PERFORM Consortium V6.0



PERFORM Consortium PARTNER: IMPERIAL COLLEGE (UK) <u>Chief investigator/PERFORM coordinator:</u> Michael Levin

<u>Principal and co-investigators; work package leads (alphabetical order)</u> Aubrey Cunnington (grant application) Tisham De (work package lead) Jethro Herberg (Principle Investigator, Deputy Coordinator, grant application) Myrsini Kaforou (grant application, work package lead) Victoria Wright (grant application, Scientific Coordinator)

Research Group (alphabetical order)

Lucas Baumard; Evangelos Bellos; Giselle D'Souza; Rachel Galassini; Dominic Habgood-Coote; Shea Hamilton; Clive Hoggart; Sara Hourmat; Heather Jackson; Ian Maconochie; Stephanie Menikou; Naomi Lin; Samuel Nichols; Ruud Nijman; Ivonne Pena Paz; Priyen Shah; Ching-Fen Shen; Clare Wilson

Clinical recruitment at Imperial College Healthcare NHS Trust (alphabetical order))

Amina Abdulla; Ladan Ali; Sarah Darnell; Rikke Jorgensen; Sobia Mustafa; Salina Persand

Imperial College Faculty of Engineering

Molly Stevens (co-investigator), Eunjung Kim (research group); Benjamin Pierce (research group)

Clinical recruitment at Brighton and Sussex University Hospitals

Katy Fidler (Principle Investigator)

Julia Dudley (Clinical Research Registrar)

Research nurses: Vivien Richmond, Emma Tavliavini

Clinical recruitment at National Cheng Kung University Hospital

Ching-Fen Shen (Principal Investigator); Ching-Chuan Liu (Co-investigator); Shih-Min Wang (Co-investigator), funded by the Center of Clinical Medicine Research, National Cheng Kung University

SERGAS Partner (Spain)

<u>Principal Investigators</u> Federico Martinón-Torres¹ Antonio Salas^{1,2}

GENVIP RESEARCH GROUP (in alphabetical order):

Fernando Álvez González¹, Cristina Balo Farto¹, Ruth Barral-Arca^{1,2}, María Barreiro Castro¹, Xabier Bello^{1,2}, Mirian Ben García¹, Sandra Carnota¹, Miriam Cebey-López¹, María José Curras-Tuala^{1,2}, Carlos Durán Suárez¹, Luisa García Vicente¹, Alberto Gómez-Carballa^{1,2}, Jose Gómez Rial¹, Pilar Leboráns Iglesias¹, Federico Martinón-Torres¹, Nazareth Martinón-Torres¹, José María Martinón Sánchez¹, Belén Mosquera Pérez¹, Jacobo Pardo-Seco^{1,2}, Lidia Piñeiro Rodríguez¹, Sara Pischedda^{1,2}, Sara Rey Vázquez¹, Irene Rivero Calle¹, Carmen Rodríguez-Tenreiro¹, Lorenzo Redondo-Collazo¹, Miguel Sadiki Ora¹, Antonio Salas^{1,2}, Sonia Serén Fernández¹, Cristina Serén Trasorras¹, Marisol Vilas Iglesias¹.

¹ Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, and GENVIP Research Group (www.genvip.org), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain.

² Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPop Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago, Galicia, Spain

³ Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Instituto de Investigaciones Sanitarias (IDIS), and Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain

<u>RSU Partner (Latvia)</u>

Principal Investigator Dace Zavadska^{1,2}

Other RSU group authors (in alphabetical order):

Anda Balode^{1,2}, Arta Bārzdiņa^{1,2}, Dārta Deksne^{1,2}, Dace Gardovska^{1,2}, Dagne Grāvele², Ilze Grope^{1,2}, Anija Meiere^{1,2}, Ieva Nokalna^{1,2}, Jana Pavāre^{1,2}, Zanda Pučuka^{1,2}, Katrīna Selecka^{1,2}, Aleksandra Sidorova^{1,2}, Dace Svile², Urzula Nora Urbāne^{1,2}.

¹Riga Stradins university, Riga, Latvia.

² Children clinical university hospital, Riga, Latvia.

Medical Research Council Unit The Gambia (MRCG) at LSHTM Partner

Principal Investigator

Effua Usuf

Additional Investigators

Kalifa Bojang Syed M. A. Zaman Fatou Secka Suzanne Anderson Anna Rocalsatou Sarr Momodou Saidykhan Saffiatou Darboe Samba Ceesay Umberto D'alessandro

Medical Research Council Unit The Gambia at LSHTM P O Box 273, Fajara, The Gambia

ERASMUS MC-Sophia Children's Hospital

Principal Investigator Henriëtte A. Moll¹

<u>Research group</u> Dorine M. Borensztajn¹, Nienke N. Hagedoorn, Chantal Tan ¹, ¹, Clementien L. Vermont², Joany Zachariasse ¹

Additional investigator W Dik ³

 ¹ Erasmus MC-Sophia Children's Hospital, Department of General Paediatrics, Rotterdam, the Netherlands
² Erasmus MC-Sophia Children's Hospital, Department of Paediatric Infectious Diseases & Immunology, Rotterdam, the Netherlands

³ Erasmus MC, Department of immunology, Rotterdam, the Netherlands

Swiss Pediatric Sepsis Study

Principal Investigators:

Philipp Agyeman, MD¹, Luregn J Schlapbach, MD, FCICM^{2,3}, Eric Giannoni, MD^{4,5}, Martin Stocker, MD⁶, Klara M Posfay-Barbe, MD⁷, Ulrich Heininger, MD⁸, Sara Bernhard-Stirnemann, MD⁹, Anita Niederer-Loher, MD¹⁰, Christian Kahlert, MD¹⁰, Giancarlo Natalucci, MD¹¹, Christa Relly, MD¹², Thomas Riedel, MD¹³, Christoph Aebi, MD¹, Christoph Berger, MD¹² **for the Swiss Pediatric Sepsis Study**

Affiliations:

¹ Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

² Neonatal and Pediatric Intensive Care Unit, Children's Research Center, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland

³Child Health Research Centre, University of Queensland, and Queensland Children's Hospital, Brisbane, Australia

⁴ Clinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital and University of Lausanne, Switzerland

⁵ Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Switzerland

⁶ Department of Pediatrics, Children's Hospital Lucerne, Lucerne, Switzerland

⁷ Pediatric Infectious Diseases Unit, Children's Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland

⁸ Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland

⁹ Children's Hospital Aarau, Aarau, Switzerland

¹⁰ Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland St. Gallen, St. Gallen, Switzerland

¹¹ Department of Neonatology, University Hospital Zurich, Zurich, Switzerland

¹² Division of Infectious Diseases and Hospital Epidemiology, and Children's Research Center, University Children's Hospital Zurich, Switzerland

¹³ Children's Hospital Chur, Chur, Switzerland

Liverpool Partner

Principal Investigators

Enitan D Carrol^{1,2,3}

Stéphane Paulus ^{1,}

Research Group (in alphabetical order):

Elizabeth Cocklin¹, Rebecca Jennings⁴, Joanne Johnston⁴, Simon Leigh¹, Karen Newall⁴, Sam Romaine¹

¹ Department of Clinical Infection, Microbiology and Immunology, University of Liverpool Institute of Infection and Global Health , Liverpool, England

² Alder Hey Children's Hospital, Department of Infectious Diseases, Eaton Road, Liverpool, L12 2AP

³ Liverpool Health Partners, 1st Floor, Liverpool Science Park, 131 Mount Pleasant, Liverpool, L3 5TF

⁴Alder Hey Children's Hospital, Clinical Research Business Unit, Eaton Road, Liverpool, L12 2AP

NKUA Partner (Greece)

Principal investigator: Professor Maria Tsolia (all activities)

Investigator/Research fellow: Irini Eleftheriou (all activities)

Additional investigators:

Recruitment: Maria Tambouratzi

Lab: Antonis Marmarinos (Quality Manager)

Lab: Marietta Xagorari

Kelly Syggelou

2nd Department of Pediatrics, National and Kapodistrian University of Athens,

"P. and A. Kyriakou" Children's Hospital

Thivon and Levadias

Goudi, Athens

Micropathology Ltd :

Dr Marie Voice Post doc scientist

Professor Colin Fink , Clinical Microbiologist

Additional investigators

Dr Marie Voice, Post doc scientist

Dr. Leo Calvo-Bado, Post doc scientist

Medical University of Graz, Austria (MUG)

Principal Investigator:

Werner Zenz¹ (all activities)

Co-investigators (in alphabetical order)

Benno Kohlmaier¹ (all activities)

Nina A. Schweintzger¹ (all activities)

Manfred G. Sagmeister¹ (study design, consortium wide sample management)

Research team

Daniela S. Kohlfürst¹ (study design)

Christoph Zurl¹ (BIVA PIC)

Alexander Binder¹ (grant application)

Recruitment team, data managers, (in alphabetical order):

Susanne Hösele¹, Manuel Leitner¹, Lena Pölz¹, Glorija Rajic¹,

Clinical recruitment partners (in alphabetical order):

Sebastian Bauchinger¹, Hinrich Baumgart⁴, Martin Benesch³, Astrid Ceolotto¹, Ernst Eber², Siegfried Gallistl¹, Gunther Gores⁵, Harald Haidl¹, Almuthe Hauer¹, Christa Hude¹, Markus Keldorfer⁵, Larissa Krenn⁴, Heidemarie Pilch⁵, Andreas Pfleger², Klaus Pfurtscheller⁴, Gudrun Nordberg⁵, Tobias Niedrist⁸, Siegfried Rödl⁴, Andrea Skrabl-Baumgartner¹, Matthias Sperl⁷, Laura Stampfer⁵, Volker Strenger³, Holger Till⁶, Andreas Trobisch⁵, Sabine Löffler⁵

Author Affiliations:

¹ Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical University of Graz, Graz, Austria

²Department of Pediatric Pulmonology, Medical University of Graz, Graz, Austria

³Department of Pediatric Hematooncoloy, Medical University of Graz, Graz, Austria

⁴Paediatric Intensive Care Unit, Medical University of Graz, Graz, Austria

⁵University Clinic of Paediatrics and Adolescent Medicine Graz, Medical University Graz, Graz, Austria

⁶Department of Paediatric and Adolescence Surgery, Medical University Graz, Graz, Austria

⁷Department of Pediatric Orthopedics, Medical University Graz, Graz, Austria

⁸Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria

London School of Hygiene and Tropical Medicine

WP 5/WP1

Principal Investigator:

Dr Shunmay Yeung^{1,2 3} PhD, MBBS, FRCPCH, MRCP, DTM&H

Research Group

Dr Juan Emmanuel Dewez¹MD, DTM&H, MSc

Mr David Bath² MSc, MAppFin, BA(Hons)

Dr Alec Miners² BA(Hons), MSc, PhD

Dr Ruud Nijman³ PhD MSc MD MRCPCH

Dr Catherine Wedderburn¹ BA, MBChB, DTM&H, MSc, MRCPCH

Ms Anne Meierford¹ MSc, BMedSc, BMBS

Dr Baptiste Leurent⁴, PhD, MSc

- Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, UK
- 2. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
- 3. Department of Paediatrics, St. Mary's Hospital Imperial College Hospital, London, UK
- 4. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

Radboud University Medical Center (RUMC), The Netherlands

Principal Investigators:

Ronald de Groot¹, Michiel van der Flier^{1,2,3}, Marien I. de Jonge¹

Co-investigators Radboud University Medical Center (in alphabetical order):

Koen van Aerde^{1,2}, Wynand Alkema¹, Bryan van den Broek¹, Jolein Gloerich¹, Alain J. van Gool¹, Stefanie Henriet^{1,2}, Martijn Huijnen¹, Ria Philipsen¹, Esther Willems¹

Investigators PeDBIG PERFORM DUTCH CLINICAL NETWORK (in alphabetical order):

G.P.J.M. Gerrits⁸, M. van Leur⁸, J. Heidema ⁴, L. de Haan^{1,2} C.J. Miedema ⁵, C. Neeleman ¹ C.C. Obihara ⁶, G.A. Tramper-Stranders7⁶

- ^{1.} Radboud University Medical Center, Nijmegen, The Netherlands
- ^{2.} Amalia Children's Hospital, Nijmegen, The Netherlands
- ^{3.} Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
- ^{4.} St. Antonius Hospital, Nieuwegein, The Netherlands
- ^{5.} Catharina Hospital, Eindhoven, The Netherlands
- ^{6.} ETZ Elisabeth, Tilburg, The Netherlands
- ^{7.} Franciscus Gasthuis, Rotterdam, The Netherlands
- ^{8.} Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Oxford team (UK)

Principal Investigators

Andrew J. Pollard^{1,2}, Rama Kandasamy^{1,2}, Stéphane Paulus^{1,2}

Additional Investigators

Michael J. Carter^{1,2}, Daniel O'Connor^{1,2}, Sagida Bibi^{1,2}, Dominic F. Kelly^{1,2}, Meeru Gurung³, Stephen Thorson³, Imran Ansari³, David R. Murdoch⁴, Shrijana Shrestha³.

Author Affiliations:

¹Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

²NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

³Paediatric Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal.

⁴Department of Pathology, University of Otago, Christchurch, New Zealand.

Newcastle University, Newcastle upon Tyne, (UK)

Principal Investigator:

Marieke Emonts ^{1,2,3} (all activities)

Co-investigators

Emma Lim^{2,3,7} (all activities)

Lucille Valentine⁴

Recruitment team (alphabetical), data-managers, and GNCH Research unit:

Karen Allen⁵, Kathryn Bell⁵, Adora Chan⁵, Stephen Crulley⁵, Kirsty Devine⁵, Daniel Fabian⁵, Sharon King⁵, Paul McAlinden⁵, Sam McDonald⁵, Anne McDonnell2,⁵, Ailsa Pickering^{2,5}, Evelyn Thomson⁵, Amanda Wood⁵, Diane Wallia⁵, Phil Woodsford⁵,

Sample processing: Frances Baxter⁵, Ashley Bell⁵, Mathew Rhodes⁵

PICU recruitment

Rachel Agbeko⁸

Christine Mackerness⁸

Students MOFICHE

Bryan Baas², Lieke Kloosterhuis², Wilma Oosthoek²

Students/medical staff PERFORM

Tasnim Araf⁶, Joshua Bennet², Kalvin Collings², Ilona van der Giessen², Alex Martin², Aqeela Rashid⁶, Emily Rowlands² Gabriella de Vries²

Engagement work/ethics/cost effectiveness

Mike Martin⁴, Ravi Mistry², Lucille Valentine⁴

Author Affiliations:

¹ Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne UK

²Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

³NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Westgate Rd, Newcastle upon Tyne NE4 5PL, United Kingdom

⁴Newcastle University Business School, Centre for Knowledge, Innovation, Technology and Enterprise (KITE), Newcastle upon Tyne, United Kingdom

⁵Great North Children's Hospital, Research Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

⁶Great North Children's Hospital, Paediatric Oncology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

⁷Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK

⁸Great North Children's Hospital, Paediatric Intensive Care Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

LMU Munich Partner (Germany)

Principal Investigator:

Ulrich von Both^{1,2} MD, FRCPCH (all activities)

Research group:

Laura Kolberg¹ MSc (all activities)

Manuela Zwerenz¹ MSc, Judith Buschbeck¹ PhD

Clinical recruitment partners (in alphabetical order):

Christoph Bidlingmaier³, Vera Binder⁴, Katharina Danhauser⁵, Nikolaus Haas¹⁰, Matthias Griese⁶, Tobias Feuchtinger⁴, Julia Keil⁹, Matthias Kappler⁶, Eberhard Lurz⁷, Georg Muench⁸, Karl Reiter⁹, Carola Schoen⁹

Author Affiliations:

¹Div. Paediatric Infectious Diseases, Hauner Children's Hospital, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany

²German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

³Div. of General Paediatrics, ⁴Div. Paediatric Haematology & Oncology, ⁵Div. of Paediatric Rheumatology, ⁶Div. of Paediatric Pulmonology, ⁷Div. of Paediatric Gastroenterology, ⁸Neonatal Intensive Care Unit, ⁹Paediatric Intensive Care Unit Hauner Children's Hospital, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany, ¹⁰Department Pediatric Cardiology and Pediatric Intensive Care, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany bioMérieux, France

Principal Investigator: François Mallet^{1,2,3}

<u>Research Group:</u> Karen Brengel-Pesce^{1,2, 3} Alexandre Pachot¹ Marine Mommert^{1,2}

¹Open Innovation & Partnerships (OIP), bioMérieux S.A., Marcy l'Etoile, France ² Joint research unit Hospice Civils de Lyon - bioMérieux, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France

³ EA 7426 Pathophysiology of Injury-induced Immunosuppression, University of Lyon1-Hospices Civils de LyonbioMérieux, Hôpital Edouard Herriot, 5 Place d'Arsonval, 69437 Lyon Cedex 3, France

Department of Infectious Diseases, University Medical Centre Ljubljana, Slovenia

Principal Investigator:

Marko Pokorn^{1,2,3} MD, PhD

Research Group:

Mojca Kolnik¹ MD, Katarina Vincek¹ MD, Tina Plankar Srovin¹ MD, PhD, Natalija Bahovec¹ MD, Petra Prunk¹ MD, Veronika Osterman¹ MD, Tanja Avramoska¹ MD

Affiliations:

¹Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, SI-1525 Ljubljana, Slovenia

²University Childrens' Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

³Department of Infectious Diseases and Epidemiology, Faculty of Medicine, University of Ljubljana, Slovenia

Amsterdam, Academic Medical Hospital & Sanquin Research Institute (NL)

Principal Investigator:

Taco Kuijpers ^{1,2}

Co-investigators

Ilse Jongerius²

Recruitment team (EUCLIDS, PERFORM):

J.M. van den Berg¹, D. Schonenberg¹, A.M. Barendregt¹, D. Pajkrt¹, M. van der Kuip^{1,3}, A.M. van Furth^{1,3}

Students PERFORM

Evelien Sprenkeler², Judith Zandstra²,

Technical support PERFORM

G. van Mierlo², J. Geissler²

Author Affiliations:

¹ Amsterdam University Medical Center (Amsterdam UMC), location Academic Medical Center (AMC), Dept of Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, the Netherlands

² Sanquin Research Institute, & Landsteiner Laboratory at the AMC, University of Amsterdam, Amsterdam, the Netherlands.

³ Amsterdam University Medical Center (Amsterdam UMC), location Vrije Universiteit Medical Center (VUMC), Dept of Pediatric Infectious Diseases and Immunology, Free University (VU), Amsterdam, the Netherlands (former affiliation)